Q&A

Regulatory Services For Accelerated Development And Commercialization

iStock-1126636492-decision-analytics

The increase in breakthrough therapy designations and other allowances for expedited regulatory review has led to ever more innovative drug products being developed under shortened timelines. Accelerated development can be particularly challenging for small and emerging biotech companies with limited resources in-house. These companies often seek support from external partners, including contract development & manufacturing organizations (CDMOs). Jakob Bonde, Head of Regulatory Affairs, Small Molecules at Lonza, discusses how the company helps customers navigate today’s regulatory environment, while shortening timelines to clinical trials and commercialization.

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: